Biotech Hunter
Biotech Hunter
Home
Companies
Trials
People
Search
Home
/
Trials
/
NCT00135317
NCT00135317
View on ClinicalTrials.gov
AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies
PHASE3
Completed
INTERVENTIONAL
Timeline
Start Date
November 30, 2004
Conditions
Cancer
Interventions
DRUG
darbepoetin alfa
Sponsors
Lead Sponsor
Amgen
All Listed Sponsors
lead
Amgen
INDUSTRY
NCT00135317 - AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies | Biotech Hunter | Biotech Hunter